Spencer Pharmaceutical Reveals Its Competitive Advantages

BOSTON, MA--(Marketwire - August 26, 2010) -

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) reveals its Competitive Advantages from the results of their research conducted at the lab at the University of Quebec at Montreal (UQAM).

Spencer reveals its competitive advantages with its oral drug applications. Spencer’s technology provides a “pain free” advantage and was found to present a noticeable versatility in terms of size and characteristics (charged or uncharged, polar or non-polar, hydrophilic or not) of the therapeutic molecule to be delivered.

“It was found that our excipient was able to formulate small-size molecules either polar (hydrophilic such as metformin or ibuprofen) or non polar (as acetaminophen) as well as medium or large-size molecules such as bioactive peptides (ex. Nisin), proteins or even microorganisms (probiotics), essentially applying to many popular Over the Counter drugs and prescribed as well,” stated Dr. Max Arella, CEO of the company.

However many of the delivery technologies for therapeutic peptides or proteins failed to overcome three major obstacles: i) Denaturation of the peptide or of the protein or bacterium by gastric acid and even by pepsin protease in the stomach environment, ii) Degradation of the peptide or protein or bacterium by the attack of proteolytic enzymes in intestine, iii) poor or limited absorption of the peptide or protein into the bloodstream (if not directed to the colon).

Spencer’s matrix is versatile, but also affords a gastro-protection against acidity and proteolysis, particularly in the case of sensitive bioactive agents (peptides, proteins, bacteria) contributing thus to their stability during the gastric and intestinal transit. In addition, it possesses the muco-adhesive properties which can prevent proteolysis and enhance their intestinal mucosal retention or uptake to the bloodstream in an active form.

By overcoming these obstacles, our technology represents a major advancement in orally peptide or protein delivery, making easier and less painful their administration, increasing the patient compliance. Due to its versatility, we believe that our technology will markedly reduce the overall costs of manufacturing effective drugs.

About Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information About Forward-Looking Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company’s website does not constitute a part of this release.